Eltrombopag-related renal vein thromboembolism in a patient with immune thrombocytopenia: A case report
Open Access
- 16 April 2021
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (11), 2611-2618
- https://doi.org/10.12998/wjcc.v9.i11.2611
Abstract
Eltrombopag is an orally administered thrombopoietin receptor agonist linked to a heightened risk of treatment-related thromboembolism. Both venous and arterial thromboses have been documented in the medical literature. In the absence of nephropathy, a 48-year-old patient receiving eltrombopag for immune thrombocytopenia (ITP) developed renal vein thrombosis and pulmonary embolism. The renal vein thrombus spontaneously resolved during subsequent anticoagulant treatment, restoring venous circulation. A rapid upsurge in platelets, rather than their absolute number, may trigger thrombotic events in this setting. For patients at high thrombotic risk, individualized eltrombopag dosing and vigilance in platelet monitoring are perhaps needed during treatment of ITP.Keywords
This publication has 18 references indexed in Scilit:
- Comparison of treatments for persistent/chronic immune thrombocytopenia: a systematic review and network meta-analysisPlatelets, 2018
- Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND studyBlood, 2017
- Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopeniaBlood Coagulation & Fibrinolysis, 2016
- Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trialsMedicina Clinica, 2015
- Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009–2013 French PharmacoVigilance assessmentEuropean Journal of Internal Medicine, 2014
- Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyBlood, 2013
- Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpuraPlatelets, 2013
- Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patientPlatelets, 2013
- Portal Vein Thrombosis during Eltrombopag Treatment for Immune Thrombocytopenic Purpura in a Patient with Liver Cirrhosis due to Hepatitis C Viral InfectionJournal of Clinical and Experimental Hematopathology, 2013
- Thrombopoietin-Receptor Agonists for Primary Immune ThrombocytopeniaThe New England Journal of Medicine, 2011